Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CDNA
stocks logo

CDNA

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
102.58M
+18.48%
0.227
+25.93%
100.63M
+18.83%
0.213
+113.33%
103.89M
+19.86%
0.242
+141.67%
Estimates Revision
The market is revising Upward the revenue expectations for CareDx, Inc (CDNA) for FY2025, with the revenue forecasts being adjusted by 1.47% over the past three months. During the same period, the stock price has changed by 40.45%.
Revenue Estimates for FY2025
Revise Upward
up Image
+1.47%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+28.66%
In Past 3 Month
Stock Price
Go Up
up Image
+40.45%
In Past 3 Month
Wall Street analysts forecast CDNA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CDNA is 22.00 USD with a low forecast of 22.00 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast CDNA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CDNA is 22.00 USD with a low forecast of 22.00 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
2 Hold
0 Sell
Moderate Buy
Current: 19.410
sliders
Low
22.00
Averages
22.00
High
22.00
Current: 19.410
sliders
Low
22.00
Averages
22.00
High
22.00
William Blair
Market Perform
initiated
2025-08-25
Reason
William Blair
Price Target
2025-08-25
initiated
Market Perform
Reason
William Blair initiated coverage of CareDx with a Market Perform rating and no price target. The firm says CareDx is a pure-play provider of solutions for transplant centers. While the shares will likely prove undervalued at current levels over the long term, a recently proposed local coverage decision impacting the company's testing services segment, which represent 75% of revenue, "clouds the near-term thesis," the analyst tells investors in a research note. Blair's analysis points to a fair value close to $20 per share.
BTIG
Buy
downgrade
$26 -> $22
2025-08-13
Reason
BTIG
Price Target
$26 -> $22
2025-08-13
downgrade
Buy
Reason
BTIG lowered the firm's price target on CareDx to $22 from $26 and keeps a Buy rating on the shares. The company delivered a roughly in-line Q2 and tightened its full-year guidance range, though the key to the earnings call was CareDx estimating the impacts of the recent Palmetto MolDx draft LCD, which proposes to limit reimbursement, the analyst tells investors in a research note.
BTIG
Mark Massaro
Buy
downgrade
$30 -> $26
2025-07-29
Reason
BTIG
Mark Massaro
Price Target
$30 -> $26
2025-07-29
downgrade
Buy
Reason
BTIG analyst Mark Massaro lowered the firm's price target on CareDx to $26 from $30 and keeps a Buy rating on the shares ahead of the Q2 earnings report. The firm is positive on the SMID cap diagnostics and specialty clinical lab group, but favors mostly the labs over tools companies, where there is a clear path of expansion in gross margins and lift in cash flow, the analyst tells investors in a research note.
Craig-Hallum
Buy
downgrade
$40 -> $26
2025-07-18
Reason
Craig-Hallum
Price Target
$40 -> $26
2025-07-18
downgrade
Buy
Reason
Craig-Hallum lowered the firm's price target on CareDx to $26 from $40 and keeps a Buy rating on the shares. The firm notes CareDx closed down 38.5% on Thursday in the wake of an unfavorable proposed Local Coverage Determination for transplant testing. Craig-Hallum thinks the shares are substantially undervalued at the current price, even if the rule is finalized.
Nephron Research
Thomas DeBourcy
Hold
to
Buy
upgrade
$28
2025-07-09
Reason
Nephron Research
Thomas DeBourcy
Price Target
$28
2025-07-09
upgrade
Hold
to
Buy
Reason
Nephron Research analyst Thomas DeBourcy upgraded CareDx to Buy from Hold with a $28 price target.
Goldman Sachs
Matthew Sykes
Strong Buy
Maintains
$34 → $26
2025-04-17
Reason
Goldman Sachs
Matthew Sykes
Price Target
$34 → $26
2025-04-17
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for CareDx Inc (CDNA.O) is 21.89, compared to its 5-year average forward P/E of 37.07. For a more detailed relative valuation and DCF analysis to assess CareDx Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
37.07
Current PE
21.89
Overvalued PE
179.26
Undervalued PE
-105.12

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
42.61
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
164.64
Undervalued EV/EBITDA
-79.42

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
4.92
Current PS
0.00
Overvalued PS
9.18
Undervalued PS
0.66
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

CDNA News & Events

Events Timeline

(ET)
2025-11-04
16:22:17
CareDx increases FY25 revenue forecast to $372M-$376M, surpassing consensus of $368.9M
select
2025-11-04
16:21:37
CareDx Announces Q3 Earnings Per Share of 28 Cents, Exceeding Consensus Estimate of 14 Cents
select
2025-10-27 (ET)
2025-10-27
07:11:18
CareDx names Jeffrey Teuteberg as its new chief medical officer.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
6.5
11-27NASDAQ.COM
Wall Street Analysts Predict 28.02% Surge for CareDx (CDNA): Trading Strategies Explained

  • Stock Performance and Price Targets: CareDx (CDNA) has seen a 24.7% increase in stock price over the past month, with a mean price target of $22.8 suggesting a potential 28% upside, although estimates vary significantly among analysts.

  • Analyst Skepticism: Investors should approach price targets with caution, as analysts often set overly optimistic targets influenced by business relationships, and empirical research indicates that these targets can mislead rather than guide investment decisions.

  • Earnings Estimates and Analyst Consensus: There is growing optimism regarding CareDx's earnings, with recent upward revisions in EPS estimates, leading to a 38.8% increase in the Zacks Consensus Estimate, which may indicate potential stock upside.

  • Investment Strategy Considerations: While price targets can provide some insight, they should not be the sole basis for investment decisions; a comprehensive analysis of fundamental factors is essential for better ROI.

[object Object]
Preview
4.0
11-06Benzinga
Insights from Three Analysts on CareDx

  • Analyst Ratings Overview: CareDx has received mixed analyst ratings over the past three months, with a total of three ratings ranging from bullish to bearish, and a recent average price target increase to $23.00.

  • Company Performance: CareDx operates as a precision medicine company focused on transplant patients, offering various testing services and achieving a revenue growth rate of 20.72% as of September 30, 2025.

  • Financial Health Indicators: The company demonstrates strong financial metrics, including a net margin of 1.67%, return on equity (ROE) of 0.52%, and return on assets (ROA) of 0.38%, all surpassing industry averages.

  • Debt Management: CareDx maintains a solid financial structure with a debt-to-equity ratio of 0.09, indicating effective debt management compared to industry norms.

[object Object]
Preview
6.0
11-06Benzinga
BTIG Reaffirms Buy Rating on CareDx, Increases Price Target to $25

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.

  • Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters, enhancing their trading strategies.

  • Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and experiences.

  • Market Winning Tools: The platform provides essential tools and information that traders use daily to succeed in the markets.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is CareDx Inc (CDNA) stock price today?

The current price of CDNA is 19.41 USD — it has increased 2.97 % in the last trading day.

arrow icon

What is CareDx Inc (CDNA)'s business?

CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the provider of genomics-based information for transplant patients. Its commercially available post-transplant testing services consist of AlloSure Kidney, a donor-derived cell-free DNA, or dd-cfDNA, solution for kidney transplant patients, AlloMap Heart, a gene expression profiling solution for heart transplant patients, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Its lab product portfolio includes QTYPE, Olerup SSP and SBT, AlloSeq Tx, AlloSeq HCT, and AlloSeq cfDNA. It also offers a diverse portfolio of digital solutions to transplant centers.

arrow icon

What is the price predicton of CDNA Stock?

Wall Street analysts forecast CDNA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CDNA is 22.00 USD with a low forecast of 22.00 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is CareDx Inc (CDNA)'s revenue for the last quarter?

CareDx Inc revenue for the last quarter amounts to 100.06M USD, increased 20.72 % YoY.

arrow icon

What is CareDx Inc (CDNA)'s earnings per share (EPS) for the last quarter?

CareDx Inc. EPS for the last quarter amounts to 0.03 USD, decreased -115.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for CareDx Inc (CDNA)'s fundamentals?

The market is revising Upward the revenue expectations for CareDx, Inc (CDNA) for FY2025, with the revenue forecasts being adjusted by 1.47% over the past three months. During the same period, the stock price has changed by 40.45%.
arrow icon

How many employees does CareDx Inc (CDNA). have?

CareDx Inc (CDNA) has 644 emplpoyees as of December 05 2025.

arrow icon

What is CareDx Inc (CDNA) market cap?

Today CDNA has the market capitalization of 998.82M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free